.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cerilliant
Dow
AstraZeneca
Federal Trade Commission
Queensland Health
QuintilesIMS
Cipla
Chubb
US Army

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022184

« Back to Dashboard

NDA 022184 describes LUMIGAN, which is a drug marketed by Allergan and is included in two NDAs. It is available from two suppliers. There are twelve patents protecting this drug and two Paragraph IV challenges. Additional details are available on the LUMIGAN profile page.

The generic ingredient in LUMIGAN is bimatoprost. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

Summary for 022184

Tradename:1
Applicant:1
Ingredient:1
Patents:12
Therapeutic Class:Ophthalmic Agents

Pharmacology for NDA: 022184

Ingredient-typeProstaglandins

Medical Subject Heading (MeSH) Categories for 022184

Suppliers and Packaging for NDA: 022184

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184 NDA Allergan, Inc. 0023-3205 0023-3205-08 1 BOTTLE, DROPPER in 1 CARTON (0023-3205-08) > 7.5 mL in 1 BOTTLE, DROPPER
LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184 NDA Allergan, Inc. 0023-3205 0023-3205-02 1 BOTTLE, DROPPER in 1 CARTON (0023-3205-02) > 2.5 mL in 1 BOTTLE, DROPPER

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION/DROPS;OPHTHALMICStrength0.01%
Approval Date:Aug 31, 2010TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jun 13, 2027Product Flag?YSubstance Flag?YDelist Request?
Patent:► SubscribePatent Expiration:Mar 16, 2025Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Mar 16, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION

Expired Orange Book Patents for NDA: 022184

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
AllerganLUMIGANbimatoprostSOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010► Subscribe► Subscribe
AllerganLUMIGANbimatoprostSOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010► Subscribe► Subscribe
AllerganLUMIGANbimatoprostSOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Queensland Health
Farmers Insurance
Deloitte
Fuji
Federal Trade Commission
Daiichi Sankyo
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot